12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
As we wrote here recently, organizations representing freelance journalists and photographers filed ...
Read More >
As states and other jurisdictions continue to implement, amend, and clarify their stay-at-home order...
Read More >
The first “funnel” is now over for the 2020 legislative session. This means if a House bill did no...
Read More >
This week in our blog series on best practices in administering benefit claims, we discuss the impor...
Read More >
Opportunity zones provide a powerful tool for taxpayers to defer recognizing their capital gains if ...
Read More >
The Securities and Exchange Commission (SEC) announced an award to an overseas whistleblower, with t...
Read More >